文献速递急性肾损伤肾小球疾病

抗中性粒细胞胞质抗体相关血管炎肾活检慢性度评分

Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis.
PubMed 文献 · Nephrol Dial Transplant · 2022-01-01

本研究为回顾性队列研究,纳入329例MPO或PR3-ANCA阳性且活动性肾病的AAV患者,应用Mayo Clinic慢性度评分(MCCS)评估肾活检慢性化程度对预后预测的价值。结果显示MCCS分级与就诊时肾功能损伤程度、无事件生存率、肾脏恢复及肾脏衰竭风险独立相关,且不受诱导治疗(环磷酰胺或利妥昔单抗)影响,MCCS≥4可作为预测肾脏衰竭的临界值。

要点

  • MCCS分级与就诊时eGFR显著负相关(P<0.0001)。
  • MCCS各组分(肾小球硬化、间质纤维化、肾小管萎缩、动脉硬化)与较低eGFR和较差无事件生存相关。
  • MCCS≥4可作为预测肾脏衰竭的临床临界值。

核心结论

  • 肾活检慢性化改变可独立预测AAV-GN患者的肾功能、结局及治疗反应。

研究设计与样本

  • 回顾性队列研究,纳入329例MPO或PR3-ANCA阳性且活动性肾病的AAV患者,应用MCCS进行肾活检慢性度评分。

主要发现

  • MCCS分级为极轻度102例(31.0%)、轻度106例(32.2%)、中度86例(26.1%)、重度35例(10.6%)。
  • 各MCCS分级对应平均eGFR分别为48.3、29.2、23.7、18.5 mL/min/1.73 m2(P<0.0001)。
  • MCCS各组分程度越高,中位eGFR越低(P<0.0001),无事件生存率越低(P值分别为0.002、P<0.0001、P<0.0001、P=0.017)。
  • MCCS分级越高,肾脏恢复率越低(P=0.001),事件更频繁,至肾脏衰竭时间更短(P<0.0001),肾脏衰竭和死亡(P<0.0001)及死亡(P=0.042)风险更高,且独立于诱导治疗(环磷酰胺或利妥昔单抗)。
  • MCCS可分层预测各分级肾脏结局,MCCS≥4可作为预测肾脏衰竭的临界值。

关键数值与推荐

  • MCCS分级与就诊时肾功能损伤程度相关:极轻度、轻度、中度、重度对应平均eGFR分别为48.3、29.2、23.7、18.5 mL/min/1.73 m2(P<0.0001)。
  • MCCS各组分(肾小球硬化、间质纤维化、肾小管萎缩、动脉硬化)程度越高,中位eGFR越低(P<0.0001),无事件生存率越低(P=0.002、P<0.0001、P<0.0001、P=0.017)。
  • MCCS分级越高,肾脏恢复率越低(P=0.001),至肾脏衰竭时间更短(P<0.0001),肾脏衰竭和死亡风险更高(P<0.0001),死亡风险更高(P=0.042)。
  • MCCS≥4可作为预测肾脏衰竭的临界值。

临床怎么用

  • 肾活检MCCS评分可用于AAV-GN患者预后评估,指导临床决策。
  • MCCS≥4提示肾脏衰竭风险高,应加强监测和干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kidney biopsy is valuable for prognostic assessment of renal outcomes in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with glomerulonephritis (AAV-GN) but the impact of chronic changes is not determined. METHODS: We conducted a retrospective cohort study of myeloperoxidase (MPO)- or proteinase 3 (PR3)-ANCA-positive patients with AAV and active renal disease. We applied the Mayo Clinic Chronicity Score (MCCS) and validated and evaluated its implications on outcome prediction in AAV-GN. RESULTS: We analyzed 329 patients with kidney biopsies available to score. The extent of chronicity was graded by MCCS as minimal [102 (31.0%)], mild [106 (32.2%)], moderate [86 (26.1%)] and severe [35 (10.6%)]. The MCCS grades correlated with the degree of renal function impairment at presentation [mean estimated glomerular filtration rate (eGFR) 48.3 versus 29.2 versus 23.7 versus 18.5 mL/min/1.73 m2, respectively; P < 0.0001]. Higher degrees of the individual components of the MCCS (glomerulosclerosis, interstitial fibrosis, tubular atrophy and arteriosclerosis) were associated with lower median eGFR (P < 0.0001) and decreased event-free [kidney failure (KF) and death] survival (P = 0.002, P < 0.0001, P < 0.0001 and P = 0.017, respectively). Patients with lower MCCS grades recovered renal function more frequently (P < 0.0001). Increasing MCCS grades were associated with decreased renal recovery (P = 0.001), more frequent events and shorter time to KF (P < 0.0001), KF and death (P < 0.0001) and death (P = 0.042), independent of the remission induction treatment used (cyclophosphamide or rituximab). The MCCS stratified renal outcomes for each MCCS grade and can be used in clinical practice as a cutoff for KF prediction (MCCS ≥4). CONCLUSIONS: Chronic changes on kidney histology independently predict renal function, outcomes and response to treatment in AAV-GN.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Casal Moura M, Fervenza FC, Specks U, et al. Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant. 2022. PMID: 34436585. doi:10.1093/ndt/gfab250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。